The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Hereditary cancer testing is a process of identifying an inherited gene mutation that increases the risk of cancer development. It mainly includes predictive genetic testing and clinical DNA sequencing, in predictive genetic testing, patient’s family history is analyzed for any inherited mutation from ancestry. In DNA sequencing, entire DNA or genome of an individual is analyzed. It is useful for testing many genetic mutations at a time.
The global Hereditary Cancer Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hereditary Cancer Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hereditary Cancer Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hereditary Cancer Testing in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hereditary Cancer Testing include Ambry Genetics (Konica Minota), Asper Biogene, Natera, Caris Life Sciences, BioReference Laboratories (GeneDx), LabSolutions, Progenity，Inc, ARUP Laboratories and Myriad, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hereditary Cancer Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Cancer Testing.
Report Scope
The Hereditary Cancer Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Cancer Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Cancer Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Ambry Genetics (Konica Minota)
- Asper Biogene
- Natera
- Caris Life Sciences
- BioReference Laboratories (GeneDx)
- LabSolutions
- Progenity，Inc
- ARUP Laboratories
- Myriad
- NeoGenomics
- Blueprint Genetics
- CellMax Life
- Fulgent Genetics
- Strand Life Sciences
- Myogenes
- LabCorp
- Quest Diagnostics
- Pathway Genomics
Segment by Type
- RNA Testing
- DNA Testing
Segment by Application
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other Cancers
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Cancer Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Cancer Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 RNA Testing
1.2.3 DNA Testing
1.3 Market by Application
1.3.1 Global Hereditary Cancer Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Gastrointestinal Cancer
1.3.4 Prostate Cancer
1.3.5 Respiratory/Lung Cancer
1.3.6 Other Cancers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hereditary Cancer Testing Market Perspective (2019-2030)
2.2 Hereditary Cancer Testing Growth Trends by Region
2.2.1 Global Hereditary Cancer Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hereditary Cancer Testing Historic Market Size by Region (2019-2024)
2.2.3 Hereditary Cancer Testing Forecasted Market Size by Region (2025-2030)
2.3 Hereditary Cancer Testing Market Dynamics
2.3.1 Hereditary Cancer Testing Industry Trends
2.3.2 Hereditary Cancer Testing Market Drivers
2.3.3 Hereditary Cancer Testing Market Challenges
2.3.4 Hereditary Cancer Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hereditary Cancer Testing Players by Revenue
3.1.1 Global Top Hereditary Cancer Testing Players by Revenue (2019-2024)
3.1.2 Global Hereditary Cancer Testing Revenue Market Share by Players (2019-2024)
3.2 Global Hereditary Cancer Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hereditary Cancer Testing Revenue
3.4 Global Hereditary Cancer Testing Market Concentration Ratio
3.4.1 Global Hereditary Cancer Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Cancer Testing Revenue in 2023
3.5 Hereditary Cancer Testing Key Players Head office and Area Served
3.6 Key Players Hereditary Cancer Testing Product Solution and Service
3.7 Date of Enter into Hereditary Cancer Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hereditary Cancer Testing Breakdown Data by Type
4.1 Global Hereditary Cancer Testing Historic Market Size by Type (2019-2024)
4.2 Global Hereditary Cancer Testing Forecasted Market Size by Type (2025-2030)
5 Hereditary Cancer Testing Breakdown Data by Application
5.1 Global Hereditary Cancer Testing Historic Market Size by Application (2019-2024)
5.2 Global Hereditary Cancer Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hereditary Cancer Testing Market Size (2019-2030)
6.2 North America Hereditary Cancer Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hereditary Cancer Testing Market Size by Country (2019-2024)
6.4 North America Hereditary Cancer Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hereditary Cancer Testing Market Size (2019-2030)
7.2 Europe Hereditary Cancer Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hereditary Cancer Testing Market Size by Country (2019-2024)
7.4 Europe Hereditary Cancer Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hereditary Cancer Testing Market Size (2019-2030)
8.2 Asia-Pacific Hereditary Cancer Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hereditary Cancer Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Hereditary Cancer Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hereditary Cancer Testing Market Size (2019-2030)
9.2 Latin America Hereditary Cancer Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hereditary Cancer Testing Market Size by Country (2019-2024)
9.4 Latin America Hereditary Cancer Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hereditary Cancer Testing Market Size (2019-2030)
10.2 Middle East & Africa Hereditary Cancer Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hereditary Cancer Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Hereditary Cancer Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ambry Genetics (Konica Minota)
11.1.1 Ambry Genetics (Konica Minota) Company Detail
11.1.2 Ambry Genetics (Konica Minota) Business Overview
11.1.3 Ambry Genetics (Konica Minota) Hereditary Cancer Testing Introduction
11.1.4 Ambry Genetics (Konica Minota) Revenue in Hereditary Cancer Testing Business (2019-2024)
11.1.5 Ambry Genetics (Konica Minota) Recent Development
11.2 Asper Biogene
11.2.1 Asper Biogene Company Detail
11.2.2 Asper Biogene Business Overview
11.2.3 Asper Biogene Hereditary Cancer Testing Introduction
11.2.4 Asper Biogene Revenue in Hereditary Cancer Testing Business (2019-2024)
11.2.5 Asper Biogene Recent Development
11.3 Natera
11.3.1 Natera Company Detail
11.3.2 Natera Business Overview
11.3.3 Natera Hereditary Cancer Testing Introduction
11.3.4 Natera Revenue in Hereditary Cancer Testing Business (2019-2024)
11.3.5 Natera Recent Development
11.4 Caris Life Sciences
11.4.1 Caris Life Sciences Company Detail
11.4.2 Caris Life Sciences Business Overview
11.4.3 Caris Life Sciences Hereditary Cancer Testing Introduction
11.4.4 Caris Life Sciences Revenue in Hereditary Cancer Testing Business (2019-2024)
11.4.5 Caris Life Sciences Recent Development
11.5 BioReference Laboratories (GeneDx)
11.5.1 BioReference Laboratories (GeneDx) Company Detail
11.5.2 BioReference Laboratories (GeneDx) Business Overview
11.5.3 BioReference Laboratories (GeneDx) Hereditary Cancer Testing Introduction
11.5.4 BioReference Laboratories (GeneDx) Revenue in Hereditary Cancer Testing Business (2019-2024)
11.5.5 BioReference Laboratories (GeneDx) Recent Development
11.6 LabSolutions
11.6.1 LabSolutions Company Detail
11.6.2 LabSolutions Business Overview
11.6.3 LabSolutions Hereditary Cancer Testing Introduction
11.6.4 LabSolutions Revenue in Hereditary Cancer Testing Business (2019-2024)
11.6.5 LabSolutions Recent Development
11.7 Progenity，Inc
11.7.1 Progenity，Inc Company Detail
11.7.2 Progenity，Inc Business Overview
11.7.3 Progenity，Inc Hereditary Cancer Testing Introduction
11.7.4 Progenity，Inc Revenue in Hereditary Cancer Testing Business (2019-2024)
11.7.5 Progenity，Inc Recent Development
11.8 ARUP Laboratories
11.8.1 ARUP Laboratories Company Detail
11.8.2 ARUP Laboratories Business Overview
11.8.3 ARUP Laboratories Hereditary Cancer Testing Introduction
11.8.4 ARUP Laboratories Revenue in Hereditary Cancer Testing Business (2019-2024)
11.8.5 ARUP Laboratories Recent Development
11.9 Myriad
11.9.1 Myriad Company Detail
11.9.2 Myriad Business Overview
11.9.3 Myriad Hereditary Cancer Testing Introduction
11.9.4 Myriad Revenue in Hereditary Cancer Testing Business (2019-2024)
11.9.5 Myriad Recent Development
11.10 NeoGenomics
11.10.1 NeoGenomics Company Detail
11.10.2 NeoGenomics Business Overview
11.10.3 NeoGenomics Hereditary Cancer Testing Introduction
11.10.4 NeoGenomics Revenue in Hereditary Cancer Testing Business (2019-2024)
11.10.5 NeoGenomics Recent Development
11.11 Blueprint Genetics
11.11.1 Blueprint Genetics Company Detail
11.11.2 Blueprint Genetics Business Overview
11.11.3 Blueprint Genetics Hereditary Cancer Testing Introduction
11.11.4 Blueprint Genetics Revenue in Hereditary Cancer Testing Business (2019-2024)
11.11.5 Blueprint Genetics Recent Development
11.12 CellMax Life
11.12.1 CellMax Life Company Detail
11.12.2 CellMax Life Business Overview
11.12.3 CellMax Life Hereditary Cancer Testing Introduction
11.12.4 CellMax Life Revenue in Hereditary Cancer Testing Business (2019-2024)
11.12.5 CellMax Life Recent Development
11.13 Fulgent Genetics
11.13.1 Fulgent Genetics Company Detail
11.13.2 Fulgent Genetics Business Overview
11.13.3 Fulgent Genetics Hereditary Cancer Testing Introduction
11.13.4 Fulgent Genetics Revenue in Hereditary Cancer Testing Business (2019-2024)
11.13.5 Fulgent Genetics Recent Development
11.14 Strand Life Sciences
11.14.1 Strand Life Sciences Company Detail
11.14.2 Strand Life Sciences Business Overview
11.14.3 Strand Life Sciences Hereditary Cancer Testing Introduction
11.14.4 Strand Life Sciences Revenue in Hereditary Cancer Testing Business (2019-2024)
11.14.5 Strand Life Sciences Recent Development
11.15 Myogenes
11.15.1 Myogenes Company Detail
11.15.2 Myogenes Business Overview
11.15.3 Myogenes Hereditary Cancer Testing Introduction
11.15.4 Myogenes Revenue in Hereditary Cancer Testing Business (2019-2024)
11.15.5 Myogenes Recent Development
11.16 LabCorp
11.16.1 LabCorp Company Detail
11.16.2 LabCorp Business Overview
11.16.3 LabCorp Hereditary Cancer Testing Introduction
11.16.4 LabCorp Revenue in Hereditary Cancer Testing Business (2019-2024)
11.16.5 LabCorp Recent Development
11.17 Quest Diagnostics
11.17.1 Quest Diagnostics Company Detail
11.17.2 Quest Diagnostics Business Overview
11.17.3 Quest Diagnostics Hereditary Cancer Testing Introduction
11.17.4 Quest Diagnostics Revenue in Hereditary Cancer Testing Business (2019-2024)
11.17.5 Quest Diagnostics Recent Development
11.18 Pathway Genomics
11.18.1 Pathway Genomics Company Detail
11.18.2 Pathway Genomics Business Overview
11.18.3 Pathway Genomics Hereditary Cancer Testing Introduction
11.18.4 Pathway Genomics Revenue in Hereditary Cancer Testing Business (2019-2024)
11.18.5 Pathway Genomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
